OR WAIT null SECS
Baxter will invest $100 million in new lyophilization equipment and an additional aseptic syringe filling line at its Halle/Westfalen (Germany) location.
Baxter International announced its plans to invest approximately $100 million in expansions to its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany on Nov. 11, 2021. The Halle/Westfalen facility is operated by Baxter BioPharma Solutions (BPS), a division of Baxter specializing in contract development and manufacturing of drug products for parenteral pharmaceuticals. Construction on the new facility is expected to begin in 2022 and complete in 2024.
The planned additions include new lyophilization equipment and a new aseptic syringe filling line. According to a company press release, the new lyophilization equipment is intended to further increase product stability and shelf life, while the additional aseptic line will help the company meet growing demand for pre-filled syringes in Europe and the United States.
“Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years,” said Marie Keeley, general manager, Baxter BioPharma Solutions, in the press release. “By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future.”
Source: Baxter International